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Abstract
Background: The pro-fibrogenic cytokine connective tissue growth factor (CTGF) plays an important role in the
development and progression of fibrosis in many organ systems, including liver. However, its role in the pathogenesis of
hepatitis C virus (HCV)-induced liver fibrosis remains unclear.
Methods: In the present study, we assessed CTGF expression in HCV-infected hepatocytes using replicon cells containing
full-length HCV genotype 1 and the infectious HCV clone JFH1 (HCV genotype 2) by real-time PCR, Western blot analysis and
confocal microscopy. We evaluated transforming growth factor b1 (TGF-b1) as a key upstream mediator of CTGF production
using neutralizing antibodies and shRNAs. We also determined the signaling molecules involved in CTGF production using
various immunological techniques.
Results: We demonstrated an enhanced expression of CTGF in two independent models of HCV infection. We also
demonstrated that HCV induced CTGF expression in a TGF-b1-dependent manner. Further dissection of the molecular
mechanisms revealed that CTGF production was mediated through sequential activation of MAPkinase and Smad-
dependent pathways. Finally, to determine whether CTGF regulates fibrosis, we showed that shRNA-mediated knock-down
of CTGF resulted in reduced expression of fibrotic markers in HCV replicon cells.
Conclusion: Our studies demonstrate a central role for CTGF expression in HCV-induced liver fibrosis and highlight the
potential value of developing CTGF-based anti-fibrotic therapies to counter HCV-induced liver damage.
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Introduction
Chronic hepatitis C virus (HCV) infection is a leading cause of
end-stage liver disease, including liver cirrhosis and hepatocellular
carcinoma, with approximately 3% of the world’s population
infected (130–170 million individuals) [1]. The main targets of
HCV infection are human hepatocytes, where HCV not only
causes an inflammatory response, but also activates pro-fibrogenic
pathways that contribute to liver fibrosis [2]. Liver fibrosis is
characterized by the production of pro-fibrogenic cytokines by
parenchymal cells (hepatocytes) and mesenchymal cells e.g.
Kupffer cells, endothelial cells, hepatic stellate cells (HSCs), which
collectively contribute to the unrelenting synthesis and deposition
of extracellular matrix (ECM) components, downregulation of
matrix metalloproteinases (MMPs) and increased expression/
action of tissue inhibitor of metalloproteinases (TIMPs) [2,3].
Together, these molecular changes determine the progression of
chronic hepatitis C to liver cirrhosis and hepatocellular carcinoma
(HCC) [1].
Recently, the profibrogenic cytokine connective tissue growth
factor (CTGF), a member of the CCN gene family (CTGF, cyr61/
cef10, nov), has been shown to play a key role in various fibrotic
disorders [3,4,5,6,7]. It is a multi-functional protein (,40 kD)
produced by various cell types that acts via autocrine or paracrine
pathways to regulate diverse cellular functions including growth,
proliferation, apoptosis, adhesion, migration, ECM production
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have, however, not been well-characterized [9]. Data reported in
recent years provides compelling evidence that CTGF is a key
factor in development of hepatic fibrosis [3,10,11,12,13,14]. With
regard to HCV infection, CTGF expression in liver biopsy
samples has been shown to correlate independently with the
fibrosis stage and plasma HCV RNA levels [11,15]. In the present
study, we investigated the role of CTGF in HCV-induced liver
fibrosis and the molecular mechanism of its production.
The fibrogenic mechanisms in the liver are dependent on the
interplay of many pro- and anti-fibrotic cytokines. CTGF is often
co-expressed with transforming growth factor b1 (TGF-b1) in
various fibrotic disorders. TGF-b1 is a key profibrogenic cytokine
in the liver, participating in many critical events leading to liver
fibrosis, such as HSC activation, hepatocyte apoptosis, ECM
formation and expression of other profibrogenic mediators.
Furthermore, TGF- b1 has also been shown to facilitate
epithelial-to-mesenchymal transition of hepatocytes that in turn
participates in the progression of liver fibrosis [16,17,18]. Clinical
studies have revealed elevated TGF-b1 serum levels in patients
with chronic hepatitis B virus (HBV)/HCV infections [19,20].
Studies in several connective tissue cell types have shown that
CTGF acts as a potent downstream mediator of TGF-b1,
modulating its functional effects [10]. However, the cross-talk
between these profibrogenic cytokines during HCV infection is not
known. In the present study, we first demonstrated the upregula-
tion of CTGF and TGF-b1 in the well-characterized Huh7.5-FL
HCV replicon system and HepG2 cells transfected with HCV
JFH1 RNA. We further investigated the inter-relationship between
TGF-b1 and CTGF in HCV infection. Our studies reveal that
HCV-stimulated CTGF is induced downstream of TGF-b1i na
MAPKinase and Smad-dependent manner and that CTGF
production drives production of key fibrosis-associated markers,
including procollagen I. The central role of CTGF production in
HCV-infected hepatocytes highlights the potential value of
developing CTGF-based anti-fibrotic therapies to counter HCV-
induced liver damage.
Materials and Methods
Antibodies
The antibodies used in the study were HCV NS5B (Alexis
Biochemicals, San Diego, CA), HCV Core (Abcam, Cambridge,
MA), HCV NS4A, TGF-b1 (Chemicon, Temecula, CA), Phos-
pho-Smad2, Phospho-Smad3, Smad2, Smad3, Phospho-P38, P-
38, Phospho-JNK, JNK, vimentin and Slug (Cell Signaling,
Danvers, MA), TGF-b receptor I, Phospho-ERK, ERK, CTGF,
Procollagen I and GAPDH (Santa Cruz Biotechnology, Santa
Cruz, CA) and a-SMA (Sigma, St. Louis, MO).
Cell cultures
In this study we used HCV- negative human hepatoma cell line
Huh7.5 cells and Huh7.5 cells harboring full genome length HCV
[Con1/FL-Neo HCV1b FL (S2204I)] (Huh7.5-FL) replicon cells
(Apath, LLC; St. Louis, MO) and propagated in complete
Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen,
Carlsbad, CA). Huh 7.5 cells represent a Huh7 subline which
are cured with interferon to render them highly permissive to
HCV replication [21]. Huh7.5-FL cells were maintained in
medium containing 750 mg/ml of Geneticin (G418) [21]. The
HepG2 cell line was grown in complete Eagle’s minimal essential
medium and used for transfection with HCV genotype 2A (JFH1;
Japanese fulminant hepatitis) RNA.
Western Blot analysis
Equivalent amounts of protein extracts were run on a 4–12%
gradient polyacrylamide gel (Invitrogen). Separated proteins were
transferred to nitrocellulose membranes, which were probed with
specific antibodies and developed using the enhanced chemilumi-
nescence detection system (GE Healthcare, Piscataway, NJ).
Quantitative reverse-transcriptase polymerase chain
reaction (RT-PCR)
RNA extraction and real-time PCR for CTGF and TGF-b1
were performed as described before [22]. Briefly, total RNA was
extracted from the Huh 7.5 or Huh7.5-FL cells, first-strand cDNA
synthesized and real-time PCR reactions performed using SYBR
Green Master Mix kit (Applied Biosystems, Forster City, CA). The
sequences of the primers used were: CTGF forward primer:
AATGCTGCGAGGAGTGGGT; CTGF reverse primer:
CGGCTCTAATC ATAGTTGGGTCT; TGF-b1 forward prim-
er: ACCTGAACCCGTGTTGCTCT; TGF-b1 reverse primer:
CTAAGGCGAAA GCCCTCAAT; GAPDH forward primer:
TGCACCACCAACTGCTTAGC; GAPDH reverse primer:
GGCATGGACTGTGGTCATGAG; TGF-b RI forward primer
ATTACCTGGACATCGGCA AC; TGF-b RI reverse primer
TTGGGCACCACATCATAGAA (Operon Biotechnology,
Huntsville, AL). Negative controls were a non-reverse transcrip-
tase reaction or a non-sample reaction. GAPDH was amplified as
an internal standard.
ELISA assays
Conditioned medium (DMEM containing 0.5% FCS) from
Huh 7.5 or Huh7.5-FL cells were collected at different time points,
centrifuged and the supernatant used for determination of
biologically active TGF-b1 protein by ELISA (BD Biosciences)
according to the manufacturer’s instructions.
Immunofluorescence
Fixed cells were stained with primary antibodies including NH1
anti-CTGF IgY (5 mg/ml) [23], HCV NS5B, NS4A; Core or anti-
TGF-b1 (1:200, Santa Cruz) followed by incubation with
secondary antibodies Alexa FluorH 568 goat-anti chicken IgY
(1:1000) or Alexa FluorH 568 goat-anti rabbit IgG (1:400) or Alexa
FluorH 488 goat-anti mouse IgG (1:400) (Invitrogen). The cells
were mounted with Vectashield Mounting Medium containing
DAPI (Vector Laboratories, Burlingame, CA), and examined by
confocal laser microscopy (LSM510, Carl Zeiss, Jena, Germany).
Transfections and DNA Constructs
To transfect HepG2 cells with full length JFH1 RNA, pJFH1-
pUC plasmid (Apath, LLC) as a DNA template and MEGAscript
T7 RNA synthesis kit (Applied Biosystems) were used. 5 mgo f
RNA was transfected into HepG2 cells using Nucleofector V
solution in an Amaxa nucleofector device (program no. T-028).
Cell lysates were collected at various time points and used for the
analysis of multiple proteins by Western blot analysis.
To determine Smad-dependent CTGF promoter activity,
Huh7.5 and Huh7.5-FL cells were transfected with plasmids
containing a secreted alkaline phosphatase (SEAP) reporter gene
fused to either the wild type CTGF promoter (nucleotides 2805 to
+17) or individual point mutants targeting the Smad site or the
basal control element (BCE-1) using Lipofectamine
TM 2000
(Invitrogen). Promoter/reporter constructs contained CCN2
promoter fragments spanning nucleotides 2805 to +17 (wild type
promoter) and mutations in the Smad element (TCAGA to
GGATC) and GGAA element (GGAAT to TCCCG) introduced
CTGF Expression in HCV Infection
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were otherwise identical to construct 2805.
SEAP reporter activity was calculated after adjustment for
differences among samples in transfection efficiency as determined
by co-transfection with a cytomegalovirus (CMV) promoter-b-
galactosidase (CMV-b-gal) reporter gene. CTGF-SEAP promoter
activity assays were performed with Phospha-Light kit and b-
galactosidase expression was determined by Galacto-star kit
(Applied Biosystems). SEAP levels were measured using an LMax
II 384 luminometer (Molecular Devices, Sunnyvale, CA).
ShRNA-mediated suppression of TGF-b1 or CTGF
Human TGF-b15 9-ACGAGC CCTGG ACACCAACTAT-
39(sense) and 39- ATAGTTGG TGTCCAGGGCTCGG 59
(antisense) or CTGF 59-CCAGCACCAGAATGTATATTAA-
39(sense) and 39- TTAATATACATTCTGGTG CTGT-59 (anti-
sense) GIPZ lentiviral shRNA plasmids or negative scrambled
shRNA (Open Biosystems, Huntsville, AL) were transfected into
Huh7.5 or Huh7.5-FL cells using Lipofectamine
TM 2000
according to the manufacturer’s instructions. Transfection effi-
ciency was monitored by co-transfection with the green fluorescent
protein (GFP)-expressing plasmid, pEGFP (Invitrogen).
Cultivation of Human hepatic stellate cells (LX2 cells)
with conditioned medium from Huh7.5 and Huh7.5-FL
cells
To analyze the role of profibrogenic cytokines in the superna-
tants of Huh7.5 and Huh7.5-FL on HSCs, we incubated hepatic
stellate cells (LX2) with the respective supernatants for 48 hrs,
after which the HSCs were lysed and analyzed for procollagen I.
LX2 cells were kindly provided by Dr. Scott Friedman (Mount
Sinai School of Medicine, New York).
Statistical analysis
All the experiments were carried out in triplicate or quadru-
plicate. Each set of experiments was repeated at least three times
with similar results in each case. Representative graphical data are
presented as mean 6 standard deviation. Student’s t test for paired
samples was used to determine statistical significance. Differences
were considered significant at p#0.05.
Results
Demonstration of active HCV replication in the HCV
culture system
Firstly, we validated the presence of active HCV at the protein
level in Huh7.5-FL cells stably expressing genome-length HCV.
The expression of core and NS4A protein in Huh7.5-FL cells was
shown by confocal microscopy (Fig. 1A) and Western blot analysis
(Fig. 1B). We also validated the findings with another HCV culture
system by transfecting the JFH-1 (HCV genotype-2) RNA into the
HepG2 cells. The expression of HCV NS5B and core protein in
HepG2 cells was confirmed by Western blot (Fig. 1C) and confocal
microscopy (Fig. 1D).
CTGF expression and secretion is increased in HCV-
infected hepatocytes
We first evaluated the expression of CTGF in Huh7.5 or
Huh7.5-FL cells after incubation in conditioned medium (DMEM
containing 0.5% FCS). After 32 hours, Huh7.5-FL cells showed a
7-fold higher expression of CTGF mRNA levels by quantitative
real time-PCR (RT-PCR) in comparison to the Huh7.5 cells
(Fig. 2A). The presence of a 38 kDa CTGF band in the medium
was significantly higher in Huh7.5-FL cells versus Huh7.5 cells as
assessed by Western blot analysis (Fig. 2B). In addition, we
demonstrated increased levels of cellular CTGF protein in
Huh7.5-FL cells at 48 hours by confocal microscopy (Fig. 2C).
Furthermore, we also used HepG2 cells transfected with the HCV
genotype 2 (JFH1) RNA to evaluate CTGF expression. Western
blot analysis of cell lysates and confocal microscopy of immuno-
stained cells indicated that CTGF production was enhanced in
JFH1-expressing cells, as compared to the control cells (Fig. 2D
and E), thus verifying that CTGF production was stimulated in
hepatocytes expressing HCV.
CTGF mediates HCV-induced expression of fibrotic
markers
In the present study, we evaluated the expression of a-smooth
muscle antigen (a-SMA), matrix-metalloprotease-2 (MMP-2),
vimentin and slug in Huh7.5-FL cells. As compared to Huh7.5
cells, the Huh7.5-FL cells expressed higher levels of a-SMA,
vimentin and slug, and showed reduced levels of MMP-2 activity
(50% reduction) (Fig. 3A) at the end of the 96-hour culture period.
We also evaluated the expression of a-SMA in HepG2 cells
transfected with JFH1 RNA and found increased levels of a-SMA
in comparison to the controls (Fig. 3B). As shown in Figure 3C,
procollagen I was upregulated in Huh7.5-FL cells, but this was
abrogated in cells transfected with CTGF shRNA plasmid, as
compared to the scrambled shRNA transfected cells, demonstrat-
ing that CTGF directly mediates the production of procollagen.
HCV-induced CTGF expression is TGF-b1 dependent
Several studies have shown that TGF-b1 is an important
mediator of CTGF expression in various cell types [10,24]. Hence,
we evaluated the role of TGF-b1 in CTGF production by
determining TGF-b1 mRNA and protein expression in Huh7.5 or
Huh7.5-FL cells after various periods of incubation in conditioned
medium. As compared to Huh7.5 cells, TGF-b1 mRNA was
enhanced approximately 4-fold in Huh7.5-FL cells as assessed by
quantitative RT-PCR (Fig. 4A). Furthermore, substantially higher
amounts of active TGF-b1 were present in the conditioned media
from Huh7.5-FL cells as compared to Huh7.5 cells at 24, 48 and
72 hours of culture in conditioned medium (Fig. 4B). Similarly,
supernatant from HepG2 cells transfected with JFH1 RNA
showed increased active TGF-b compared to control samples
(Fig. 4C). We also confirmed the enhanced expression of TGF- b1
precursor in Huh7.5-FL versus Huh7.5 cells by confocal
microscopy (Fig. 4D). In addition, we analyzed the expression of
TGF-b1 precursor in HepG2 cells transfected with JFH1 RNA.
Figure 4E shows the enhanced expression of TGF-b1 precursor in
JFH1-transfected HepG2 cells by confocal microscopy.
To establish the functional significance of TGF-b1 in CTGF
production, Huh7.5 or Huh7.5-FL cells were transfected with
either TGF-b1 or non-targeting shRNA plasmid. This treatment
resulted in diminished TGF-b1 precursor protein levels in cell
lysates, as expected, but also a concomitant decrease in CTGF
secretion (Fig. 5A). Furthermore, treatment of the Huh7.5-FL cells
with TGF-b1 neutralizing antibody resulted in highly diminished
CTGF levels in conditioned medium (Fig. 5B). Taken together,
these data indicated that elevated CTGF expression in HCV-
infected hepatocytes is mediated through TGF-b1. As shown in
Figure 5A (third panel), upregulation of procollagen I was
abrogated in Huh7.5-FL cells transfected with TGF-b1 shRNA
when compared with Huh7.5-FL cells transfected with scrambled
shRNA. We further analyzed the role of profibrogenic cytokines
on fibrotic marker expression in HSCs. Conditioned medium from
Huh7.5 and Huh7.5FL cells were cocultured along with LX2
CTGF Expression in HCV Infection
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nearly two fold increase of procollagen I in LX2 cells incubated
with medium from Huh7.5-FL cells compared to LX2 cells
incubated with medium from Huh 7.5 cells.
Signaling pathways that mediate HCV-induced CTGF-
production via TGF-b1
We further explored the HCV-induced signaling mechanisms
that mediate CTGF expression downstream of TGF-b1i n
Huh7.5-FL cells. Previous studies have shown that TGF-b1
mediates its functional effects by binding to the TGF-b1-receptor
Figure 1. Detection of active HCV replication in HCV-infected cell lines. (A) Huh7.5 or Huh7.5-FL cells grown for 48 h were stained with
antibodies against HCV proteins (HCV core or NS4A), followed by FITC-coupled secondary antibodies and detected using confocal microscopy. (B)
Lysates of cells grown for 48 hours were analyzed for expression of HCV core, NS4A or NS5B by Western blotting. HepG2 cells were transfected with
JFH-1 RNA and expression of HCV NS5B and core protein was analyzed by Western blotting (C) and confocal microscopy respectively (D). Equal
protein loading in the Western blot analyses was verified using GAPDH antibody. Data are from one of three independent experiments performed in
triplicate.
doi:10.1371/journal.pone.0046526.g001
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PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e46526Figure 2. HCV induces CTGF expression in Huh7.5-FL cells. (A) RNA from Huh7.5 or Huh7.5-FL cells was used in the SYBR green real-time PCR
to analyze CTGF expression. ** P,0.001 versus Huh7.5 cells. (B) Conditioned medium from Huh7.5 or Huh7.5-FL cells incubated for various time
periods was collected, concentrated and equal amounts of protein subjected to SDS-PAGE and analyzed for CTGF by Western blotting. Albumin was
used as a internal control. (C) Huh7.5 or Huh7.5-FL cells were grown for 48 hours, after which the cells were fixed, permeabilized and treated with
anti-CTGF followed by FITC-coupled secondary antibodies and examined using an Olympus FV1000 confocal microscope. HepG2 cells were
transfected with JFH1 RNA and CTGF expression was analyzed by (D) Western blotting and (E) confocal microscopy respectively. Equal protein
loading was verified using antibodies against GAPDH. Data represent mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0046526.g002
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PLOS ONE | www.plosone.org 5 October 2012 | Volume 7 | Issue 10 | e46526Figure 3. CTGF stimulates the expression of fibrotic markers in Huh7.5-FL cells. (A) Huh7.5 or Huh7.5-FL cells were incubated in
conditioned medium (medium containing 0.5%FCS) for ninety-six hours and the cell lysates were blotted to examine a-SMA expression, vimentin and
slug expression. Equal protein loading was verified using GAPDH antibody. The conditioned medium was used for the measurement of MMP-2
activity by zymography assay. (B) HepG2 cells were transfected with or without JFH-1RNA for different time points and cell lysates were blotted for a-
Sma I protein. GAPDH was used as an internal control. (C) Lysates of Huh7.5 or Huh7.5-FL cells transfected with non targeting or CTGF shRNA for
48 hrs were blotted for CTGF, procollagen I or GAPDH. The bar graphs show the quantitative analysis of CTGF or procollagen I expression relative to
that of GAPDH. * P#0.05 versus Huh7.5-FL cells. Data represent mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0046526.g003
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present study, we demonstrated the increased expression of TGF-
b1 receptor I (TGFbR1/ALK5) in Huh7.5-FL cells and also in
HepG2 cells transfected with JFH-1 RNA over the first 36 hours
of culture by Western blot (Fig. 6A & 6D) and RT-PCR (Fig. 6B).
To assess whether this difference was reflected in downstream
Figure 4. HCV induces TGF-b1 expression in Huh7.5-FL cells. (A) RNA was extracted from Huh7.5 or Huh7.5-FL cells which were incubated in
conditioned medium for 32 hrs were used in SYBR green real-time PCR to analyze TGF-b1. + P,0.05 versus Huh7.5 control. (B) Huh7.5 or Huh7.5-FL
cells were incubated for various time points and active TGF-b1 was measured in the culture supernatants by ELISA. * P#0.05 versus Huh7.5 cells. (C)
HepG2 cells were transfected with or without JFH-1 RNA and supernatants were collected at different time points to measure the TGF-b1
concentration in supernatant by ELISA. (D) Huh7.5 or Huh7.5-FL cells were fixed, permeabilized and stained with TGF-b1 antibody followed by FITC-
coupled secondary antibody, and examined by confocal microscopy. (E) HepG2 cells transfected with or without JFH1 RNA were analyzed for TGF-b1
expression by confocal microscopy. Data are from one of three independent experiments performed in triplicate.
doi:10.1371/journal.pone.0046526.g004
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Smad3 in Huh7.5 and Huh7.5-FL cells. We observed a significant
increase in Smad2 and Smad3 phosphorylation in Huh7.5FL cells
compared to Huh 7.5 cells (Fig. 6C) after various time points of
incubation in conditioned medium. Previous studies in other cell
types showed that TGF-b-mediated induction of CTGF mRNA
relies on the functional Smad element in the CTGF promoter and
that, while the BCE-1 site is involved with basal CTGF promoter
activity, it is also indirectly responsive to TGF-b since it is a
Figure 5. HCV-induced CTGF expression is TGF-b1-dependent. (A) Lysates of Huh7.5 or Huh7.5-FL cells transfected with non-targeting or
TGF-b1 ShRNA for 48 hrs were blotted to determine expression of TGF-b1, CTGF or procollagen I (upper panel). Equal protein loading was
determined using GAPDH antibody. The bar graph shows the quantitative analysis of TGF-b1, CTGF or procollagen I expression relative to that of
GAPDH (lower panel). * P#0.05 versus Huh7.5-FL cells. (B) Medium from Huh7.5 or Huh7.5-FL cells incubated for 48 hrs with anti-TGF-b1 or non-
immune IgG was collected, concentrated and equal amounts of protein were used for Western blot analysis using CTGF antibody (upper panel). The
bar graph shows the quantitative analysis of CTGF expression obtained by densitometry (lower panel). * P#0.05 versus Huh7.5 cells. (C) Human
hepatic stellate cells (LX2 cells) were co cultured with medium from Huh7.5 and Huh7.5-FL cells for 48 hrs and cell lysates were analyzed for
procollagen I expression. GAPDH was used as an internal control. For all experiments, data represent mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0046526.g005
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PLOS ONE | www.plosone.org 8 October 2012 | Volume 7 | Issue 10 | e46526Figure 6. Expression of CTGF in Huh7.5-FL cells is Smad-dependent. Cell lysates from Huh7.5 or Huh7.5-FL cells were collected at different
time points and blotted with anti-TGF-bRI (A) or phospho-Smad 2, phospho-Smad3 and total Smad2/3 antibodies (C). The bar graphs show the
quantitative analyses of TGF-b RI and p-smad2 protein expression as obtained by densitometry. RNA from Huh7.5 or Huh7.5-FL cells was used in the
reverse transcriptase PCR to analyze the TGF-b RI expression (B). (D) HepG2 cells were transfected with and without JFH-1 RNA. The cell lysates were
collected at different time points and blotted for TGF-bRI. (E) Huh7.5 and Huh7.5-FL cells were transfected with different CTGF promoter/SEAP
reporter constructs for 48 hrs. CTGF promoter activity was determined by measuring SEAP reporter expression. ** P,0.001 versus Huh7.5 cells; +
P,0.05 versus Huh7.5 cells; and ## P,0.001 versus Huh7.5-FL cells. Data represent mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0046526.g006
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PLOS ONE | www.plosone.org 9 October 2012 | Volume 7 | Issue 10 | e46526Figure 7. p38 MAP kinase mediates CTGF expression in Huh7.5-FL cells. (A) Lysates from Huh7.5 or Huh7.5-FL cells collected at the
indicated time points were blotted with Phospho-p38, Phospho-JNK, Phospho-ERK, p38, JNK and ERK antibodies. The bar graph shows the
quantitative analysis of p38 activation relative to the total p38 production assessed by densitometry. * P#0.05 versus Huh7.5 cells. (B) Huh7.5 or
Huh7.5-FL cells were pretreated with p38 MAPkinase inhibitor (SB220025; 50 mM) for 36 hours, after which cells were lysed and blotted with
antibodies to phospho-p38, p38, CTGF, Phospho-Smad2, or Smad2. The bar graph shows the quantitative analysis of the data obtained by
densitometry (left panel). * P#0.05 versus Huh7.5-FL cells. (C) Similarly HepG2 cells were transfected with and without JFH1 RNA and cells were
treated with p38 MAPKinase inhibitor (SB220025) for 24 hrs ,after which the cell lysates were analyzed for activation of p38 and Smad2. Data
represent mean 6 SD of 3 independent experiments.
doi:10.1371/journal.pone.0046526.g007
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is essential for TGF-b to induce CTGF [25,26].
Next, to determine the elements in the CTGF promoter
involved downstream of HCV-induced TGF-b1, we transfected
Huh7.5 or Huh7.5-FL cells with CTGF promoter reporters that
were either wild-type (805) or that contained point mutations in
either the BCE-1 (a response element that is indirectly regulated
by TGF-b1) or the Smad binding site (which is directly controlled
by TGF-b1). First, we found that the level of wild-type CTGF
promoter activity in lysates from the Huh7.5-FL cells was
approximately 10-fold higher than in those from Huh7.5 cells
(Fig. 6E), consistent with earlier data showing enhanced CTGF
mRNA and protein production in the Huh7.5-FL cells (Fig. 2).
Secondly, the mutant promoter activities were substantially
attenuated, an effect that was particularly evident in the
Huh7.5-FL cells, resulting in reduction in activity of 95% or
90% respectively (Fig. 6E).
We next investigated the involvement of the major MAPkinase
pathways previously implicated in TGF-b1-induced signaling in
hepatocytes. We found that p38 MAPkinase was significantly
activated in Huh7.5-FL cells in comparison to the Huh7.5 cells, as
demonstrated by an increase in phosphorylation at 36 hours
(Fig. 7A) of incubation in conditioned medium. There was no
major increase in the HCV-induced activation of JNK and ERK
1/2 in Huh7.5-FL cells, as compared to Huh7.5 cells (Fig. 7A). To
further investigate the importance of p38 MAPkinase in HCV-
induced CTGF production, Huh7.5 or Huh7.5-FL cells were pre-
treated with SB220025, a pharmacologic inhibitor of p38
MAPkinase. The reduction in p38 MAPkinase activation
(Fig. 7B, first panel) was associated with a concomitant decrease
in CTGF protein in conditioned medium (Fig. 7B, third panel).
These data clearly suggest the involvement of p38 MAPkinases in
HCV-induced CTGF production. Furthermore, we analyzed the
cross-talk between p38 MAPkinase and the Smad pathway. We
found that Huh7.5-FL cells showed reduced Smad2 phosphory-
lation in the presence of the specific p38 MAPkinase inhibitor,
when compared to control Huh7.5-FL cells (Fig. 7B, panels 4 and
5). To further confirm the role of p38 MAPKinase inhibitor, we
used HepG2 cells transfected with control and JFH-1 RNA. As
shown in Figure 7C, we also observed significant reduction of p-
p38 as well as p-Smad2 in JFH-1 transfected cells. This finding
indicates that the phosphorylation of Smad proteins is regulated by
p38 MAP kinase. Together, these studies indicate that CTGF
production occurs downstream of TGF-b1 and involves a
signaling pathway consisting of p38 MAPkinase and Smad group
of proteins.
Figure 8. Proposed hypothesis on the role of CTGF in HCV-induced liver fibrosis. We hypothesize that HCV infection in hepatocytes
induces TGF-b1 expression. TGF-b1, in turn mediates an enhanced expression of profibrogenic cytokine CTGF through Smad phosphorylation and
p38 MAP kinase activation. CTGF may further act in a paracrine manner on hepatic stellate cells (HSCs) or in an autocrine manner on hepatocytes and
drive expression of fibrotic markers including collagen and a-Sma.
doi:10.1371/journal.pone.0046526.g008
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HCV infection is among the leading causes of chronic liver
disease. Approximately one third of patients with chronic HCV
infection develop significant fibrosis, and many of them develop
cirrhosis with a high risk of hepatic decompensation or develop-
ment of HCC [1]. However, very little is known about the
mechanisms by which the virus causes hepatic fibrosis. In this
study, we have elucidated for the first time the molecular
mechanism of CTGF expression and its role as a mediator of
fibrogenesis during HCV infection.
Previously, investigations into the pathogenesis of HCV have
been hampered by the lack of in vitro and appropriate in vivo model
systems. However, in the past decade, the establishment of HCV
replicons and an infectious cell culture model have allowed for a
better understanding of the viral life cycle, pathogenesis of HCV
infection and development of antiviral strategies. These two model
systems have been widely used to analyze the HCV-mediated
mechanisms that lead to liver damage [21,27]. In the present
study, we have shown enhanced expression of CTGF in Huh7.5-
FL replicon cells (HCV genotype I) in comparison to Huh7.5 cells.
Several previous studies have compared Huh7.5-FL and Huh7.5
cells to study HCV pathogenic mechanisms [28,29]. In addition,
we also used HepG2 cells transfected with JFH1 (HCV genotype
2) to demonstrate increased CTGF expression. Of the six HCV
genotypes, viable replicons have been reported for genotype 1 and
2 strains [30]. Hence, we have confirmed increased CTGF
expression with both HCV genotypes 1 and 2.
CTGF is a multi-functional protein that drives many cellular
processes, but has received special focus with respect to its fibrotic
actions in several organs systems. In our study, we have shown that
CTGF mediates enhanced expression of fibrotic markers during
HCV infection. Specifically, increased expression of several
fibrotic markers were observed in Huh7.5-FL cells and CTGF
shRNA was effective in reducing procollagen I expression. CTGF
produced in response to HCV may act locally on non-
parenchymal cells, such as HSCs or myofibroblasts as well as
hepatocytes to enhance expression of markers that are associated
with fibrosis. Though recent studies have indicated an association
between CTGF immunostaining intensity and stage of fibrosis in
patients with chronic HCV infection and high levels of CTGF in
plasma and liver biopsy samples of HCV infected patients [11,15],
we provide for the first time, clear evidence for the role of CTGF-
induced expression of fibrotic markers in HCV infection. Our
findings demonstrating increased CTGF expression in HCV-
infected hepatocytes also underscore the importance of hepato-
cytes in producing CTGF during HCV infection. Previous studies
have indicated the contribution of parenchymal liver cells to
CTGF production in normal and diseased liver [14,24].
We also investigated the signaling and transcriptional regulatory
pathways involved in CTGF expression in HCV-infected hepato-
cytes. CTGF expression in fibrotic tissue is shown to be either
TGF-b1-dependent or independent [10,24,31]. Our results show
that TGF-b1 upregulates CTGF expression in HCV-infected
hepatocytes. The mechanism involved in HCV-induced TGF-b1
production has been well studied. HCV has been shown to
regulate TGF-b1 expression by modulating Ca
2+ signaling and
generation of reactive oxygen species (ROS), which acts through
p38 MAP kinase, ERK and JNK and NF-k-B signaling pathways
to induce TGF-b1 [32,33]. In the present study, we demonstrate
the downstream mediators of TGF-b1 that induce CTGF
production. TGF- b1 is known to mediate its functional effects
through the Smad group of proteins. We have shown increased
phosphorylation of Smad2 in Huh7.5-FL as well as in JFH-1
transfected HepG2 cells compared to control cells. We further
demonstrated that TGF-b1-mediated CTGF- production in
Huh7.5-FL cells was Smad-dependent as reduced activity was
observed in CTGF promoter reporters in which the Smad or BCE
sites were mutated. This is in agreement with recent studies which
indicate that TGF-b1-driven CTGF gene expression in other cell
types is dependent upon a functional Smad element in the CTGF
promoter as well as a BCE element which responds indirectly to
TGF-b1 [25]. MAPkinases are downstream signaling partners of
TGF-b1 and recently MAPK signaling has been shown to directly
regulate CTGF expression in fibroblasts [34]. We showed that
activation of p38 MAPkinase, but not of JNK kinase or ERK
kinase, is important in HCV-induced CTGF production. Previ-
ously, p38 MAPkinase was shown to be enhanced in HepG2 cells
transfected with HCV core protein [13]. Together, these findings
suggest HCV may mediate CTGF production by modulating
Smad and p38 MAPkinase dependent pathways.
Based on our studies, we propose a HCV-induced fibrotic
pathway in hepatocytes whereby there is an enhanced expression
of profibrogenic cytokine CTGF mediated by TGF-b1 through
Smad phosphorylation and p38 MAP kinase activation. CTGF, in
turn, may act in a paracrine manner on hepatic stellate cells
(HSCs) or in an autocrine manner on hepatocytes and drive
expression of fibrotic markers including collagen (Fig. 8). Collec-
tively, our data support a role for CTGF as a downstream
mediator of the fibrogenic actions of TGF-b1 in promotion of
ECM production. The beneficial effect of CTGF knockdown by
gene silencing through shRNA has been shown independently in
two models of rat liver fibrosis [35,36]. Our studies underscore the
importance of CTGF in HCV-mediated fibrotic pathology and
may facilitate the development of anti-fibrotic strategies in
chronic-HCV infected patients.
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